Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 352Neoplasm Metastasis 31Stomach Neoplasms 30HER2-positive Breast Cancer 19Neoplasms 16Breast Neoplasms, Male 16Brain Neoplasms 13Inflammatory Breast Neoplasms 12Esophageal Neoplasms 10Colorectal Neoplasms 10Triple Negative Breast Neoplasms 8Adenocarcinoma 7Prostatic Neoplasms 6Cardiotoxicity 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Lung Neoplasms 5Carcinoma, Ductal, Breast 5Biliary Tract Neoplasms 5Salivary Gland Neoplasms 4Pathologic Complete Response 4Pancreatic Neoplasms 4Meningeal Neoplasms 4Colonic Neoplasms 4Breast Diseases 4Recurrence 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Gallbladder Neoplasms 3Carcinoma, Lobular 3

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Breast Carcinoma × Trastuzumab × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡